Hong Kong Stock Market Movement | CStone Pharmaceuticals-B(02616) rose over 5% in early trading. Its subsidiary's CS2009 Phase II clinical trial application has been approved by the U.S. FDA.

LootboxPhobia · 2026-02-20T07:04:37+00:00

Jiangsu Chia Tai Pharmaceutical-B Shares rose more than 5% in early trading, as its core asset CS2009 received FDA approval for Phase II clinical trials in advanced solid tumors. The development of this trispecific antibody is progressing well, with Phase I study data already published, and its safety and anti-tumor activity are worth noting.

LootboxPhobia

2026-02-20 07:04:37

Abstract generation in progress

Insight Finance APP reports that CStone Pharmaceuticals-B (02616) rose over 5% in early trading. As of the time of writing, it increased by 4.74%, trading at HKD 6.19, with a turnover of HKD 26.5456 million.

On the news front, CStone Pharmaceuticals announced that the IND application for its core asset CS2009 for Phase II clinical trials in advanced solid tumors has been approved by the FDA. CS2009 (a tri-specific antibody targeting PD-1/VEGF/CTLA-4) for Phase II clinical trials in advanced solid tumors has received FDA approval, marking a significant milestone in the global development of this innovative immunotherapy.

The announcement states that preliminary data from Phase I clinical studies of CS2009 were presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showing good safety and tolerability, with positive anti-tumor activity data. More Phase I and Phase II clinical data are expected to be released at the upcoming American Society of Clinical Oncology (ASCO) and ESMO meetings this year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes